ArticleJournal of drug assessment2017

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.

Randeep Sangha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.